virus
possess
class
fusion
protein
requir
proteolyt
activ
host
cell
proteas
mediat
fusion
host
cell
membran
mammalian
gene
encod
proteas
inhibitor
target
trypsinlik
serin
proteas
show
proteas
inhibitor
restrict
activ
effici
rang
influenza
virus
human
metapneumoviru
hmpv
treatment
result
cleavag
fusion
inhibit
fulllength
influenza
ha
influenzalik
ill
ili
repres
signific
burden
public
health
caus
rang
respiratori
virus
addit
influenza
viru
ongo
goal
antivir
drug
discoveri
develop
broadlyact
therapeut
use
absenc
definit
diagnosi
case
ili
strategi
succeed
drug
target
share
across
viru
famili
need
identifi
inhibit
assay
trypsin
typic
resid
intestin
tract
express
broad
activ
toward
differ
ha
subtyp
hmpv
f
serv
control
addit
furin
use
neg
control
inhibit
none
peptid
use
combin
aforement
proteas
furin
cleavag
site
test
furinmedi
cleavag
peptid
hpai
cleavag
motif
presenc
nm
supplementari
figur
continu
measur
vmax
valu
proteasepeptid
combin
presenc
differ
concentr
plot
obtain
vmax
valu
concentr
logarithm
scale
supplementari
figur
use
softwar
determin
reflect
concentr
vmax
respect
reaction
inhibit
half
cleavag
inhibit
repres
cleavag
site
trypsin
result
valu
nm
tabl
inhibit
efficaci
toward
matriptas
hat
rang
nm
nm
tabl
howev
inhibit
much
less
effici
plasmin
compar
trypsin
nm
observ
similar
trend
test
peptid
mimick
ha
cleavag
site
use
trypsin
hat
plasmin
trypsin
matriptas
plasmin
respect
tabl
except
plasmin
found
human
respiratori
tract
proteas
inhibit
higher
efficaci
compar
trypsin
expand
analysi
peptid
mimick
ha
cleavag
site
lpai
hpai
reflect
result
describ
tabl
cleavag
inhibit
ha
significantli
differ
observ
made
trypsin
tabl
test
inhibit
hmpv
cleavag
trypsin
matriptas
demonstr
high
inhibit
efficaci
three
test
proteas
measur
trypsin
matriptas
nm
nm
nm
respect
tabl
compar
valu
observ
peptid
mimick
influenza
ha
cleavag
site
motif
valu
hmpv
f
peptid
low
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
vivo
situat
requir
valid
express
fulllength
fusion
protein
cell
cultur
model
test
cleavag
cleavag
inhibit
respect
proteas
howev
conduct
experi
want
ensur
cytotox
effect
cell
therefor
cell
incub
variou
concentr
time
period
hour
pb
serv
cytotox
neg
posit
control
respect
observ
slight
reduct
cell
viabil
ad
cell
figur
test
cleavag
inhibit
fulllength
ha
express
cell
ad
recombin
matriptas
proteas
preincub
trypsin
respect
proteas
without
incub
use
control
cleavag
analyz
via
western
blot
signal
intens
band
quantifi
use
control
sampl
without
incub
refer
point
illustr
rel
cleavag
ha
without
inhibitor
figur
bd
trypsin
cleav
test
ha
protein
high
effici
observ
matriptas
figur
howev
ha
cleav
matriptas
similar
extent
without
led
rel
cleavag
reduct
matriptas
respect
figur
b
cleavag
ha
reduc
preincub
use
figur
c
test
cleavag
inhibit
matriptas
ha
substrat
found
spint
reduc
cleavag
cleavag
respect
compar
control
figur
contrast
effect
cleavag
ha
reduc
rel
cleavag
approxim
figur
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
order
determin
whether
also
prevent
cleavag
hmpv
f
first
examin
proteas
addit
trypsin
abl
cleav
hmpv
f
first
cotransfect
full
length
hat
matriptas
hmpv
f
vero
cell
f
protein
radioact
label
methionin
cleavag
examin
quantifi
full
length
protein
cleavag
product
found
hat
abl
effici
cleav
hmpv
f
matriptas
decreas
express
f
though
clear
due
gener
degrad
protein
lower
initi
express
howev
matriptas
demonstr
potenti
lowlevel
cleavag
cotransfect
figur
b
examin
cleavag
exogen
proteas
matriptas
compar
trypsin
control
matriptas
abl
cleav
hmpv
f
figur
agreement
peptid
assay
cleavag
hmpv
f
matriptas
less
effici
trypsin
peptid
fulllength
protein
assay
demonstr
cleav
hmpv
f
also
serv
confirm
matriptas
like
cleav
hmpv
f
coexpress
matriptas
may
alter
protein
synthesi
stabil
turnov
express
synthesi
transport
cell
surfac
next
test
inhibit
exogen
proteas
trypsin
matriptas
preincub
proteas
ad
vero
cell
express
hmpv
f
analyz
cleavag
product
format
preincub
minim
affect
cleavag
concentr
addit
result
inhibit
trypsin
matriptasemedi
cleavag
hmpv
similar
find
ha
figur
f
present
biochem
experi
demonstr
abl
effici
inhibit
proteolyt
cleavag
hmpv
f
sever
influenza
ha
subtyp
varieti
proteas
function
analysi
determin
whether
inhibit
prevent
cell
cell
fusion
viral
growth
examin
influenza
infect
cell
cultur
hmpv
import
human
pathogen
influenza
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
grow
significantli
better
cell
cultur
compar
hmpv
first
test
whether
cleavag
inhibit
result
inhibit
cellcel
fusion
describ
matriptas
preincub
subsequ
ad
vero
cell
express
ha
ha
cell
briefli
expos
low
ph
buffer
induc
fusion
subsequ
analyz
use
immun
fluoresc
assay
matriptas
test
incub
vero
cell
express
ha
still
observ
syncytia
format
figur
howev
result
abrog
syncytia
format
trigger
cleavag
respect
ha
matriptas
made
observ
test
ha
figur
matriptasemedi
ha
syncytia
format
inhibit
addit
figur
ensur
cellcel
fusion
inhibit
result
ha
cleavag
inhibit
side
effect
treatment
per
se
express
ha
vero
cell
treat
inhibitor
ha
possess
hpai
cleavag
site
cleav
intracellularli
furin
matur
process
inhibit
furin
abl
cross
cell
membran
thu
interfer
proteolyt
process
ha
therefor
control
allow
examin
whether
interfer
cellcel
fusion
figur
show
ha
form
larg
syncytia
absenc
well
presenc
nm
henc
conclud
direct
inhibitori
effect
cellcel
fusion
understand
whether
abl
inhibit
reduc
growth
viru
cell
cultur
model
cours
hour
transfect
cell
human
human
matriptas
two
major
proteas
shown
respons
activ
distinct
influenza
subtyp
virus
essenti
viru
propag
mice
play
major
role
activ
virus
matriptas
cleav
ha
subtyp
specif
manner
involv
ccbyncnd
intern
licens
made
avail
vivo
cleavag
ha
result
describ
suggest
role
matriptas
activ
hour
post
transfect
infect
mdck
cell
moi
subsequ
ad
protein
differ
concentr
nontransfect
cell
serv
control
exogen
trypsin
ad
facilit
viral
propag
supernat
harvest
hour
post
infect
viral
titer
subsequ
analyz
use
plaqu
assay
initi
mitig
trypsinmedi
growth
concentr
extent
inhibit
slightli
increas
higher
concentr
figur
tabl
highest
test
concentr
reduc
viral
growth
log
figur
tabl
observ
similar
pattern
cell
transfect
human
matriptas
figur
tabl
growth
inhibit
start
concentr
applic
growth
reduc
approxim
log
figur
tabl
infect
cell
express
ad
viral
growth
significantli
reduc
concentr
addit
led
reduct
viral
growth
log
figur
tabl
also
test
whether
could
reduc
growth
viru
major
circul
season
influenza
subtyp
howev
matriptas
seem
activ
virus
henc
trypsin
ad
growth
medium
cell
infect
compar
control
cell
without
ad
inhibitor
significantli
inhibit
trypsinmedi
growth
concentr
figur
tabl
highest
concentr
viral
growth
reduc
log
figur
also
examin
effect
inhibit
hmpv
spread
time
vero
cell
infect
rghmpv
moi
subsequ
treat
trypsin
everi
hour
cell
scrape
amount
viru
present
titer
trypsin
replenish
daili
find
untreat
cell
infect
demonstr
signific
spread
convers
cell
infect
treat
detect
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
viru
minim
viru
detect
demonstr
significantli
inhibit
hmpv
viral
replic
spread
figur
antivir
therapi
often
appli
patient
alreadi
show
sign
diseas
therefor
test
abl
reduc
viral
growth
ad
cell
hour
initi
infect
cell
infect
moi
trypsin
ad
promot
viral
growth
time
infect
also
ad
one
sampl
second
sampl
receiv
hour
post
infect
growth
supernat
harvest
hour
later
viral
growth
analyz
found
viral
growth
significantli
reduc
regardless
whether
ad
time
infect
hour
later
figur
tabl
influenza
viru
caus
four
pandem
sinc
earli
th
centuri
infect
million
peopl
year
season
flu
result
death
annual
vaccin
effort
proven
challeng
due
antigen
drift
viru
emerg
resist
phenotyp
moreov
efficaci
vaccin
seem
significantli
reduc
certain
highrisk
group
preval
antivir
therapi
treat
influenza
virusinfect
patient
adamantan
neuraminidas
inhibitor
target
viral
protein
increas
number
report
circul
influenza
subtyp
resist
treatment
hmpv
caus
infect
upper
lower
respiratori
tract
express
similar
symptom
influenza
infect
result
signific
morbid
mortal
suscept
group
young
children
older
adult
peopl
immunocompromis
current
treatment
hmpv
infect
avail
studi
focus
novel
approach
use
antivir
therapi
target
host
factor
rather
viral
protein
offer
broad
potenti
effect
therapeut
approach
demonstr
potent
inhibitor
serinetyp
proteas
abl
significantli
inhibit
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
cleavag
hmpv
f
ha
impair
hatrigg
fusion
cell
henc
reduc
growth
variou
influenza
strain
cell
cultur
assess
cleavag
hmpv
fusion
protein
vitro
use
peptid
cleavag
assay
modifi
previous
work
viral
fusion
protein
hmpv
f
peptid
cleav
trypsin
plasmin
matriptas
unabl
cleav
confirm
find
system
entir
hmpv
f
protein
subject
cleavag
coexpress
fusion
protein
hat
matriptas
proteas
treat
f
exogen
proteas
matriptas
find
first
identifi
proteas
besid
trypsin
abl
cleav
hmpv
f
addit
hmpv
appear
util
mani
serin
proteas
influenza
use
ha
process
therefor
offer
strong
potenti
antivir
target
demonstr
greater
advantag
inhibitor
host
proteas
eg
aprotinin
shown
effect
antivir
also
seem
specif
subset
proteas
argu
specif
proteas
inhibitor
inhibit
one
proteas
might
advantag
may
result
less
side
effect
respect
influenza
infect
could
repres
specif
target
shown
major
activ
proteas
mice
human
airway
cell
howev
evid
applic
broadspectrum
proteas
inhibitor
result
sever
side
effect
specif
one
side
effect
may
consequ
proteas
inhibit
compound
may
act
differ
target
bodi
report
demonstr
crucial
viru
propag
mice
cell
cultur
suggest
also
play
major
role
human
respiratori
tract
far
howev
unclear
whether
obtain
result
translat
human
studi
shown
exampl
human
matriptas
abl
process
peptid
assay
suggest
wide
varieti
host
proteas
specif
except
plasmin
test
proteas
combin
peptid
mimick
cleavag
site
differ
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
cleavag
inhibit
hmpv
f
substanti
lower
picomolar
rang
suggest
hmpv
cleavag
may
select
inhibit
howev
western
blot
data
show
addit
lowest
concentr
nm
result
cleavag
inhibit
hmpv
f
test
proteas
differ
sensit
influenza
ha
hmpv
requir
investig
pose
sever
potenti
advantag
inhibitor
target
host
proteas
cell
cultur
studi
show
exampl
matriptasemedi
ha
cleavag
effici
inhibit
concentr
contrast
substrat
rang
aprotinin
serin
proteas
inhibitor
shown
reduc
influenza
infect
target
host
proteas
seem
limit
synthet
peptidelik
molecul
design
inhibit
specif
serin
proteas
hat
test
proteas
potenti
inhibit
proteas
relev
influenza
activ
remain
unclear
current
promis
antivir
protein
inhibitor
camostat
alreadi
approv
japan
treatment
chronic
pancreat
recent
demonstr
camostat
inhibit
influenza
replic
cell
cultur
prevent
viral
spread
pathogenesi
sarscov
mice
inhibit
serin
proteas
howev
camostat
appli
prior
viru
infect
administ
mice
via
oral
gavag
previou
studi
show
significantli
attenu
influenza
infect
mice
use
concentr
lower
describ
camostat
concentr
intranas
administr
suffici
current
studi
suggest
abl
significantli
inhibit
viral
spread
ongo
infect
need
appli
prior
start
infect
mous
studi
also
show
appli
directli
respiratori
tract
camostat
current
distribut
pill
therefor
less
organ
specif
addit
camostat
synthet
wherea
natur
occur
molecul
may
attenu
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
potenti
advers
effect
due
nonn
compound
activ
immun
system
futur
research
conduct
test
appli
effici
via
inhal
explor
potenti
side
effect
mice
studi
howev
test
potenti
inhibit
viral
replic
cell
cultur
model
abl
achiev
growth
reduct
approxim
log
hour
concentr
one
potenti
explan
unabl
satur
proteas
present
individu
experi
suffici
prevent
viral
growth
addit
continu
overexpress
matriptas
may
produc
artifici
high
quantiti
protein
exceed
inhibitori
capac
problem
could
solv
either
use
higher
concentr
optim
inhibitori
properti
howev
data
also
demonstr
abil
inhibit
proteas
express
cell
surfac
inhibit
limit
proteas
ad
exogen
incub
inhibitor
figur
express
cytotox
effect
concentr
significantli
therapeut
dosag
requir
inhibit
comparison
studi
concentr
use
nanomolar
rang
publish
inhibitor
requir
micromolar
concentr
howev
believ
futur
research
allow
fulli
util
potenti
broadspectrum
antivir
therapi
wu
et
al
recent
describ
kunitz
domain
respons
inhibit
matriptas
futur
studi
explor
whether
inhibitori
capabl
condens
small
peptid
may
improv
efficaci
abil
inhibit
broad
rang
serin
proteas
involv
activ
influenza
suggest
base
antivir
therapi
could
effici
pathogen
exampl
play
major
role
pathogenesi
also
requir
activ
sarscov
merscov
hmpv
current
treatment
option
virus
limit
therefor
could
becom
viabl
option
potenti
antivir
therapeut
fulli
exploit
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
howev
therapeut
potenti
treat
ili
caus
virus
requir
activ
trypsinlik
serin
proteas
may
limit
provid
treatment
option
infect
caus
influenza
hpai
virus
virus
believ
activ
furin
proprotein
convertas
belong
class
subtilisinlik
proteas
preliminari
data
lab
demonstr
inhibit
furinmedi
cleavag
hpai
cleavag
site
peptid
mimic
well
peptid
carri
describ
furin
cleavag
site
data
shown
addit
furin
act
intracellularli
evid
abl
penetr
cell
membran
thu
inhibit
proteas
locat
intracellular
compart
therefor
seem
unlik
abl
inhibit
furin
cell
culturebas
studi
vivo
experi
conclus
believ
potenti
develop
novel
antivir
therapi
contrast
similar
drug
synthet
endogen
express
protein
product
confer
resist
varieti
pathogen
virus
potenti
deliv
directli
respiratori
tract
aerosol
importantli
demonstr
abil
significantli
attenu
ongo
viral
infect
cell
cultur
research
conduct
explor
time
period
demonstr
highest
efficaci
cell
plasmid
virus
protein
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
mm
hepe
cellgro
fetal
bovin
serum
vwr
vero
cell
use
hmpv
experi
maintain
dmem
hyclon
supplement
fb
sigma
plasmid
encod
ha
gener
describ
plasmid
encod
hmpv
f
gener
describ
plasmid
encod
ha
human
human
matriptas
purchas
sino
biolog
inc
plasmid
encod
ha
gener
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
donat
david
steinhauer
virus
propag
egg
recombin
proteas
purchas
describ
express
purif
express
purifi
describ
minor
modif
brief
e
coli
ril
arctic
express
cell
agil
transform
cell
grown
l
luria
broth
contain
kanamycin
od
cell
chill
ice
protein
express
induc
mm
iptg
cell
grown
night
cell
harvest
protein
purifi
previous
describ
protein
elut
incub
glycerol
ad
elut
protein
final
concentr
protein
aliquot
store
protein
concentr
determin
analyz
differ
dilut
sdspage
gel
along
defin
concentr
bsa
ng
gel
stain
coomassi
scan
chemidoc
imag
system
biorad
band
quantifi
use
imag
lab
softwar
biorad
concentr
dilut
determin
base
bsa
concentr
final
concentr
calcul
base
averag
differ
dilut
peptid
assay
carri
describ
sequenc
hmpv
f
peptid
mimick
hmpv
f
cleavag
site
use
assay
enprqsrfvl
includ
nand
ctermin
modif
describ
ha
peptid
vmax
calcul
graph
replic
microsoft
excel
determin
slope
reaction
everi
concentr
nm
nm
nm
nm
nm
nm
nm
nm
nm
nm
vmax
valu
plot
graphpad
prism
softwar
concentr
produc
neg
sigmoid
graph
concentr
vmax
inhibit
half
could
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
extrapol
peptid
proteas
mixtur
sinc
xaxi
concentr
invers
log
taken
number
calcul
nm
cytotox
assay
perform
cell
count
dojindo
molecular
technolog
accord
manufactur
instruct
brief
approx
x
cell
seed
per
well
plate
grown
night
ad
indic
concentr
dmem
use
control
hour
later
solut
ad
well
incub
hour
absorb
nm
measur
use
spark
micropl
reader
tecan
per
sampl
treatment
three
technic
replic
use
averag
count
one
biolog
replic
experi
conduct
three
time
vero
cell
transfect
pdna
use
lipofectamin
plu
reagent
invitrogen
optimem
gibco
accord
manufactur
protocol
follow
day
cell
wash
pb
starv
cysteinemethionin
defici
media
min
radiolabel
cysteinemethionin
hour
cell
lyse
ripa
lysi
buffer
process
describ
previous
fusion
protein
hmpv
immunoprecipit
use
antihmpv
f
monoclon
antibodi
john
william
u
pitt
sampl
run
sdspage
visual
use
typhoon
imag
system
band
densitometri
conduct
use
imagequ
softwar
ge
repositori
respect
secondari
antibodi
tag
invitrogen
western
blot
membran
scan
use
chemidoc
imag
system
biorad
quantif
pixel
intens
individu
band
measur
use
imagej
softwar
cleavag
effici
calcul
follow
equat
nm
nm
x
cellcel
fusion
assay
carri
describ
mdck
cell
seed
confluenc
plate
one
plate
transform
plasmid
allow
express
human
matriptas
human
one
plate
transform
empti
vector
hour
post
transfect
cell
infect
respect
egggrown
viru
moi
approx
differ
concentr
ad
indic
nm
trypsin
ad
cell
transform
empti
vector
hour
post
infect
supernat
collect
centrifug
store
viral
titer
determin
use
immuneplaqu
assay
describ
vero
cell
plate
plate
follow
day
cell
infect
moi
rghmpv
hour
cell
wash
pb
optimem
without
tpcktrypsin
ad
incub
hour
trypsin
replenish
new
optimem
everi
hour
time
point
media
aspir
optimem
ad
cell
follow
scrape
flash
freez
sampl
titer
confluent
vero
cell
dilut
calcul
viral
titer
graph
show
independ
replic
intern
duplic
plot
individu
point
data
point
shown
due
sampl
loss
minimum
point
per
group
independ
replic
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
hepatocyt
growth
factor
activ
inhibitor
bikunin
gene
frequent
hypermethyl
human
hepatocellular
carcinoma
cancer
re
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
analysi
perform
use
nonpair
student
ttest
compar
sampl
test
nm
respect
sampl
incub
nm
error
bar
indic
standard
deviat
indic
p
figur
hat
matriptas
cleav
hmpv
f
abl
prevent
cleavag
exogen
proteas
hmpv
f
either
express
alon
cotransfect
proteas
allow
express
cell
metabol
starv
cystein
methionin
follow
radioact
label
protein
hour
presenc
tpcktrypsin
specifi
proteas
treat
proteas
incub
room
temperatur
minut
place
onto
cell
hour
radioact
gel
quantifi
use
imagequ
softwar
percent
cleavag
equal
b
cotransfect
proteas
hat
matriptas
abl
cleav
hmpv
f
c
exogen
proteas
matriptas
abl
cleav
hmpv
f
e
f
prevent
cleavag
hmpv
f
trypsin
matriptas
nm
concentr
demonstr
loss
cleavag
product
statist
analysi
perform
use
oneway
anova
follow
student
ttest
bonferroni
multipl
comparison
test
correct
p
p
p
p
n
valu
repres
independ
replic
treatment
group
error
bar
repres
sd
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
antibodi
secondari
fluorogen
antibodi
nuclei
stain
use
dapi
magnif
c
vero
cell
express
ha
cleav
matur
process
cell
ad
nm
nm
time
transfect
magnif
human
matriptas
human
allow
express
protein
hour
cell
express
human
matriptas
b
human
c
infect
moi
differ
concentr
ad
well
nontransfect
cell
trypsin
ad
serv
control
mdck
cell
infect
moi
trypsin
ad
assist
viral
propag
differ
concentr
ad
indic
hour
infect
supernat
collect
use
immunoplaqu
assay
determin
viral
load
experi
repeat
three
time
dot
repres
viral
titer
singl
experi
statist
analysi
perform
use
nonpair
student
ttest
compar
control
h
respect
sampl
error
bar
indic
standard
deviat
indic
p
extend
horizont
line
within
error
bar
repres
mean
valu
three
independ
replic
complet
duplic
data
point
plot
within
graph
statist
analysi
perform
use
student
ttest
p
p
p
p
nd
indic
sampl
limit
detect
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
